Clinical trial · Observational
Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy
A Retrospective Study of Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Ruptured Hepatocellular Carcinoma
NCT06247293CI-TRIAL-00073799unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with ruptured liver cancer and bleeding after surgical resection were included according to the criteria of admission, and the patients were divided into experimental and control groups. the primary efficacy end point was RFS, and the secondary end point was the rate of abdominal implant metastases and OS.To analyze the efficacy of HIPEC.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hyperthermic Intraperitoneal Chemotherapy | — | UNRESOLVED | — |
| Ruptured Liver | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intraperitoneal hyperthermic perfusion chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy
- description
- Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy
- interventionNames
- Procedure: intraperitoneal hyperthermic perfusion chemotherapy
- label
- simple surgical resection
- description
- Control group: simple surgical resection
- interventionNames
- Procedure: intraperitoneal hyperthermic perfusion chemotherapy
- label
- other
- description
- imple interventional hemostasis group
- interventionNames
- Procedure: intraperitoneal hyperthermic perfusion chemotherapy
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. according to the clinical diagnostic criteria of primary liver cancer (2022 edition) or confirmed by pathology/cytology; 2. preoperative diagnosis of rupture and hemorrhage of liver cancer by clinical manifestation, examination and imaging; 3. Age 18-80 years; 4. Child-pugh class A or class B after liver protection and albumin correction, without severe heart, lung or renal dysfunction, without absolute contraindication to surgery; 5. ECOG-PS score of 0-1; 6. without other neoplastic diseases; 7. Sign and perfect the informed consent form before operation; 8. without postoperative liver failure, without major complications such as massive hemorrhage, purulent infection and multiple organ failure, and without discharge from hospital. Exclusion Criteria: 1. having other active malignant tumor; 2. the expected survival time is less than 3 months; 3. Child-pugh class C, complicated with severe organic disease of important organs, complicated with severe cirrhosis.
References
Publications (0)
Data not yet available
No reference posted for this study.